Close

ADC Contract & IRB Management


  • Director of Research to coordinate initial contact and site visit
  • Regulatory Affairs Specialist to coordinate IRB submission/regulatory packet
  • Business manager to coordinate contract review
  • 48 hour turnaround for contract review
  • Central or local IRB capability for all studies
  • 10 day turnaround for Central IRB submission
  • 3-4 week turnaround for hospital IRB submission for inpatient studies.
  • Recognize the importance of quick turnaround for contract review & IRB submission
Close

ADC Project Management


  • Coordinator readily available for initiation/monitoring visits and investigator meetings
  • Coordinator manages all aspects of the clinical trial from site initiation to study closure
  • Coordinator acts as central contact person for patient and sponsor interaction following site initiation
  • Accurate and prompt completion of case report forms
  • Monitoring area with fax, phone and computer modem access
  • Multiple daily Airborne and Fed Ex pick up
  • Remote Data Entry capabilities and experience
  • Labcorp affiliations for Lab work
Close

Our Sponsors/CRO's


  • NIH Sponsored CLEVER
  • AHRQ/NYU Sponsored OWEMR study
  • Aastrom sponsored Critical Limb Ischemia study
  • Medical University Of South Carolina Sponsored Study on Cryotherapy
  • Advanced Biohealing -DEVO Study
  • Synovis DFU study
  • Cytomedix sponsored study
  • Onchomycosis study sponsored by Site Management Solutions

Aiyan Clinical Trials

Technology, Invested

Center for Diabetes Clinical Research under Aiyan Diabetes Center provides study coordination and research assistants to assist the center with clinical research in Diabetes and Diabetic Neuropathy.

The history of diabetes is rich with examples of the importance of clinical research. Today, a patient diagnosed with type 1 diabetes can choose from a variety of insulin formulations, and patients with type 2 diabetes can choose from a rapidly expanding armamentarium of oral drugs. New developments are on the horizon, ranging from inhaled insulin to islet transplantation, and from gene therapy to stem cells. These will need to be formally tested in rigorous clinical research before they can become part of the daily lives of people with diabetes.

Facts about Diabetes

23.6 million People or 8 percent of the U.S. population has diabetes. 5.7 million people are not diagnosed. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. About 60 to 70 percent of people with diabetes have mild to severe forms of diabetic nerve damage. Severe forms of diabetic nerve damage can lead to lower-extremity amputations.

Today, a patient diagnosed with type 1 diabetes can choose from a variety of insulin formulations, and patients with type 2 diabetes can choose from a rapidly expanding armamentarium of oral drugs. New developments are on the horizon, ranging from inhaled insulin to islet transplantation, and from gene therapy to stem cells. These will need to be formally tested in rigorous clinical research before they can become part of the daily lives of people with diabetes.

Every 30 seconds, a lower limb is lost to amputation due to diabetes related complications.

After an amputation, the chance of another amputation within 3 to 5 years is as high as 50 percent, according to the National Diabetes Education Program.

Foot problems can help doctors discover diabetes. Calluses, blisters, or dry and cracked skin anywhere on the foot can imply poor circulation.

Comprehensive foot care programs can reduce amputation rates by 45 percent to 85 percent

80,000 amputations per year can be prevented!

Established in 2005, we strive to improve the Quality of life for Patients diagnosed with Diabetes Mellitus and Foot ulcers and we are one of the fastest growing multi-specialty research organization in Augusta GA.

Our unique business model has proven to produce high quality data for sponsors and research organizations while creating great opportunities for our staff and investigators. ADC has established an extensive network of experienced, certified investigators who are dedicated to excellence in clinical research and understand the importance of involved oversight. We comprise of a Group of experienced physicians who are knowledgeable of the Code of Federal Regulations and Good Clinical Practices and are well accomplished in conducting clinical research protocols while adhering to sponsor goals and timelines.

ADC’s mission is to advance quality patient care in the treatment of Foot disorders and other Diabetes related medical diseases in our community through investigational drug and device technologies.

News & Events

What’s happening with us

  • Aiyan Diabetes Center has received the IRB institutional Review Board approval for the Dermasciences, Integrium Diabetes Foot Ulcer study. SIV site initiation visit is on March 7th, 2013.
  • Aiyan Diabetes Center and Medical University of South Carolina has established a consortium agreement: Online Behavioral coaching to promote physical activity in Leg Ulcer.
  • Aiyan Diabetes Center and Georgia now Georgia Health Sciences University has entered into Professional Service agreement for their Nurse Practitioners in Augusta and Athens.
  • Dermasciences has selected two more Aiyan Diabetes Center locations; Royston and Athens apart from Evans.
Join our Study ?
To voluteer our study, you must be 18-68 years. Apart from this, there are more things must be consider before taking you to study. The volunteers must follow several steps and you must fix an appointment with our clinical trial center. Fix an appointment
Connect With Us

© Copyright Aiyan Clinical Trials. All Rights Reserved
HomeClinical TrialsResearch FacilitiesContact UsSitemap
Website design & developed by Edatic